APA:
Copy. (2022). Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. BMC PSYCHIATRY, 22(1), 0-0. SID. https://sid.ir/paper/1074127/en
Vancouver:
Copy. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. BMC PSYCHIATRY[Internet]. 2022;22(1):0-0. Available from: https://sid.ir/paper/1074127/en
IEEE:
Copy, “Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial,” BMC PSYCHIATRY, vol. 22, no. 1, pp. 0–0, 2022, [Online]. Available: https://sid.ir/paper/1074127/en